PVLA
The table below shows Palvella Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$25.01M | -$10.84M | -$13.70M | -$59.93M | -$7.66M | -$45.90M |
| Capital expenditure | - | - | $171.00K | $1.04M | $949.00K | $2.73M |
| Investing cash flow | - | - | $12.00M | -$21.24M | -$949.00K | $39.21M |
| Dividends paid | - | - | - | - | - |
Palvella Therapeutics, Inc. reported operating cash flow of -$25.01M for fiscal year 2025. That is down 130.7% from -$10.84M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$15.06K (FY 2014) to -$25.01M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$660.00K | $87.09M | $5.00M | $7.21M | $59.13M | $10.12M |